The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension

Luis Ruilope, Angie Schaefer, Luis Ruilope, Angie Schaefer

Abstract

Introduction: Central blood pressure (BP), an important measure of cardiovascular risk, has been shown to be effectively reduced by calcium channel blockade with amlodipine (AML) plus renin-angiotensin system blockade by the angiotensin-converting enzyme inhibitor, perindopril (PER). The aim of the SEVITENSION study was to compare the central effects of PER/AML against renin-angiotensin system blockade with the angiotensin II receptor blocker olmesartan (OLM) plus AML.

Methods: In this multicenter, parallel group, non-inferiority study, patients received AML 10 mg during a 2- to 4-week run-in before randomization to 24 weeks of double-blind treatment with the fixed-dose combination of OLM/AML 40/10 mg or PER/AML 8/10 mg. Hydrochlorothiazide was added at Weeks 4, 8, or 12 in patients with inadequate BP control. The primary efficacy variable was the absolute change in central systolic BP (CSBP) from baseline to the final examination, measured by radial artery applanation tonometry and analyzed by parametric analysis of covariance. Secondary variables included 24-h ambulatory and seated BP measurements as well as BP normalization.

Results: Of 600 patients enrolled, 486 were randomized (244 to OLM/AML 40/10 mg, 242 to PER/AML 8/10 mg). The reduction in CSBP was larger with OLM/AML (14.5 ± 0.83 mmHg) than with PER/AML (10.4 ± 0.84 mmHg). The between-group difference was -4.2 ± 1.18 mmHg with 95% confidence intervals (-6.48 to -1.83 mmHg) within the predefined non-inferiority margin (2 mmHg). An integrated superiority test confirmed that OLM/AML was superior to PER/AML (p < 0.0001) in reducing CSBP. The superiority of OLM/AML over PER/AML was also established for the majority of secondary efficacy variables; at the final examination, 75.6% of OLM/AML recipients achieved BP normalization (mean seated systolic BP/diastolic BP <140/90 mmHg) compared with 57.5% of PER/AML recipients (p < 0.0001).

Conclusion: The combination of OLM/AML was superior to PER/AML in reducing CSBP and other efficacy measures, including a significantly higher rate of BP normalization.

Trial registration: ClinicalTrials.gov NCT01101009.

Figures

Fig. 1
Fig. 1
Patient flow. AE adverse events, AML amlodipine, BP blood pressure, FAS full analysis set, OLM olmesartan, PER perindopril, PPS per protocol set, SAF safety analysis set
Fig. 2
Fig. 2
Absolute change from Week 0 to the final examination in mean central systolic blood pressure by treatment group (LOCF approach for the PPS). AML amlodipine, CSBP central systolic blood pressure, LOCF last observation carried forward, OLM olmesartan; PER perindopril, PPS per protocol set
Fig. 3
Fig. 3
Forest plot of the differences between patients treated with OLM/AML 40/10 mg and PER/AML 8/10 mg in the absolute change from Week 0 to final examination in CSBP in the primary efficacy endpoint (PPS) and the FAS. P values represent the comparison between OLM/AML and PER/AML. Filled circles indicate the position of the point estimates for between-group differences and vertical lines indicate the 95% confidence intervals. AML amlodipine, BP blood pressure, CI confidence interval, FAS full analysis set, OLM olmesartan, PER perindopril, PPS per protocol set
Fig. 4
Fig. 4
Forest plot of the differences between patients treated with OLM/AML 40/10 mg and PER/AML 8/10 mg in the absolute change from Week 0 to the final examination in secondary a systolic BP parameters and b diastolic BP parameters. P values represent the superiority comparison between OLM/AML and PER/AML in the FAS. Filled circles indicate the position of the point estimates for between-group differences and vertical lines indicate the 95% confidence intervals. AML amlodipine, BP blood pressure, CI confidence interval, DBP diastolic blood pressure, FAS full analysis set, OLM olmesartan, PER perindopril, SBP systolic blood pressure
Fig. 5
Fig. 5
Proportion of patients with blood pressure normalized at the final examination using criteria based upon the 2007 ESH/ESC guidelines (SBP/DBP AML amlodipine, CKD chronic kidney disease, DBP diastolic blood pressure, ESC European Society of Cardiology, ESH European Society of Hypertension, FAS full analysis set, OLM olmesartan, PER perindopril, SBP systolic blood pressure

References

    1. Sharman JE, Laurent S. Central blood pressure in the management of hypertension: soon reaching the goal? J Hum Hypertens. 2013;27:405–411. doi: 10.1038/jhh.2013.23.
    1. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225. doi: 10.1161/CIRCULATIONAHA.105.606962.
    1. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906. doi: 10.1016/S0140-6736(05)67185-1.
    1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151.
    1. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
    1. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25:1327–1336. doi: 10.1097/HJH.0b013e3280825625.
    1. Malacco E, Omboni S, Volpe M, Auteri A, Zanchetti A. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010;28:2342–2350. doi: 10.1097/HJH.0b013e32833e116b.
    1. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68:1239–1272. doi: 10.2165/00003495-200868090-00005.
    1. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29:11–25. doi: 10.2165/0044011-200929010-00002.
    1. Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604. doi: 10.1016/j.clinthera.2008.04.002.
    1. Ruilope LM, Schaefer A. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: rationale and design of the SEVITENSION study. Contemp Clin Trials. 2011;32:710–716. doi: 10.1016/j.cct.2011.04.011.
    1. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. doi: 10.1097/HJH.0b013e3281fc975a.
    1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens. 2009;27:2121–2158. doi: 10.1097/HJH.0b013e328333146d.
    1. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority (CPMP/EWP/482/99). 2000: European Agency for the Evaluation of Medicinal Products. . Accessed Nov 14, 2013.
    1. Omboni S, Malacco E, Mallion JM, Volpe M, Zanchetti A, Study G. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. J Hypertens. 2012;30:1468–1477. doi: 10.1097/HJH.0b013e32835466ac.
    1. Pauca AL, O’Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001;38:932–937. doi: 10.1161/hy1001.096106.
    1. O’Rourke MF, Pauca AL. Augmentation of the aortic and central arterial pressure waveform. Blood Press Monit. 2004;9:179–185. doi: 10.1097/00126097-200408000-00002.
    1. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27:461–467. doi: 10.1097/HJH.0b013e3283220ea4.
    1. Oliveras A, Garcia-Ortiz L, Segura J, et al. Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. J Hypertens. 2013;31:103–108. doi: 10.1097/HJH.0b013e32835ac7b5.
    1. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197–203. doi: 10.1161/HYPERTENSIONAHA.107.089078.
    1. Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol. 2008;51:2432–2439. doi: 10.1016/j.jacc.2008.03.031.
    1. Williams B, Lacy PS. Central aortic pressure and clinical outcomes. J Hypertens. 2009;27:1123–1125. doi: 10.1097/HJH.0b013e32832b6566.
    1. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–2172. doi: 10.1097/.
    1. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049–2051. doi: 10.1016/S0140-6736(04)16456-8.
    1. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006;47:547–551. doi: 10.1016/j.jacc.2005.09.031.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj